Why Your Gift Matters
Early detection and minimally invasive treatment represent the future of gastrointestinal cancer care. Innovation in this vital field remains chronicallly underfunded. Philanthropy accelerates medical breakthroughs that traditional funding pathways cannot reach.
The Innovation: Next - Generation AXIOS™
Dr. Binmoeller has done this before. AXIOS™ transformed minimally invasive therapy globally. Now, he and the original AXIOS™ engineer have designed what they believe can become the next generation of AXIOS™, with the potential to reshape how gastrointestinal cancers are detected and treated.
Your gift directly fuels this work at a critical inflection point. By connecting the vision of the inventor with the precision of the engineer, we accelerate the journey toward patient impact.
The AXIOS™ Stent and Electrocautery Enhanced Delivery System
Funding Priorities
01
Engineering
Device engineering and refinement.
02
Preclinical
Preclinical testing and validation.
03
Regulatory
Regulatory preparation and pathway development.
04
Clinical Translation
Device engineering and refinement.
05
Patient Access
Device engineering and refinement.
Regenerative Endoscopy Initative
Restoring Function Using Autologous Biologics
The Endovision Foundation is advancing a second major innovation platform: regenerative endoscopy, focused on restoring a patient's own biologics. This work represents a new frontier in minimally invasive therapy — one that could reshape how chronic gastrointestinal disease is treated.
This work is ideally suited for outpatient centers, where minimally invasive, biologic-based therapies can be delivered without hospitalization.
Cellular Regeneration
Current Pilot Study: Autologous PRP Therapy
Dr. Binmoeller is conducting a 15-subject feasibility and safety pilot study evaluating endoscopic delivery of autologous platelet-rich plasma (PRP) in patients with refractory gastrointestinal fistulas, strictures, and chronic ulcers that fail conventional medical therapy.
Feasibility
Practical feasibility of endoscopic biologic delivery
Safety
Safety assessment in real-world GI conditions
Foundation
Foundation for expanded use of autologous biologics in the GI tract
This pilot is the beginning of a larger vision: a regenerative endoscopy platform that could ultimately transform treatment for chronic diseases such as diabetes, and potentially cancer, by harnessing biologics to restore tissue function from within the body.
Gift Levels & Impact
Research Associate
Supports initial engineering prototypes and design iterations.
Innovation Partner
Fuels preclinical testing and validation phases
Clinical Champion
Accelerates clinical translation and first-in-human pilot studies.
Frequency
One time
Monthly
Yearly
Amount
$50
$100
$200
$1,000
Other
0/100
Help Build the Future of Minimally Invasive Care
When you have a moment, please visit the Endovision Foundation website — the 501(c)(3) that Dr. Binmoeller founded to incubate visionary endoscopic platforms designed to treat disease from within the body.